Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia

Diagnostic Pathology

Weiwei Gao¹  Lin Jin¹  Yingchun Wang¹  Rong Xu¹  Xiaohua Yin²  Jingfang Shi¹ 

[1] Department of Ultrasound, Jiading Center Hospital, Shanghai 201800, China;Department of Radiology, Jiading Center Hospital, No.1 Chengbei Road, Jiading District, Shanghai 201800, China

关键词: Contrast agents;    Benign prostatic hyperplasia;    Contrast enhanced ultrasound;   

Others  :  870283
DOI  :  10.1186/1746-1596-9-133

 received in 2014-02-24, accepted in 2014-06-05,  发布年份 2014

【 摘 要 】

Background

This study aimed to investigate the clinical significance of contrast enhanced ultrasound (CEUS) in diagnosis of benign prostatic hyperplasia (BPH) through comparing CEUS parameters between BPH and normal person.

Methods

A retrospective study of sixty BPH patients (aged 73.5 ± 20.5 years old) and thirty normal controls without prostate diseases (aged 75.3 ± 19.7 years old) who had accepted CEUS detection were performed. Time-intensity curves were obtained for all tests in regions of interest. Images were processed using ACQ software and the following parameters were obtained: arrival time (AT), peak intensity (P), time to peak (TP), area under the curve (AUC), mean transit time (MTT) and extinction time (ET). Differences in inner and outer gland of prostate between BPH and the normal tissue were evaluated.

Results

There was a clear boundary between the inner and outer gland of BPH prostate. AT, TP, MTT, ET and P in BPH outer gland were significantly higher than the control group. In inner gland, MTT, ET, AUC and P were also significantly higher than the controls. The accurate rate to diagnose BPH using CEUS was 95.6%, and the sensitivity and specificity were 95.0% and 96.7%, respectively.

Conclusions

Among these significantly changed parameters, the increases of MTT, ET and AUC in inner gland and AT, TP in outer gland were most likely related to BPH. These parameters provide an objective visual assessment to diagnosis of BPH.

【 授权许可】

   
2014 Shi et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Wei JT, Calhoun EA, Jacobsen SJ: Benign prostatic hyperplasia. Urologic Diseases in America 2004, 5:43.
• [2]Benign prostatic hyperplasia (BPH) [http://www.health.am/cr/benign-prostatic-hyperplasia/#1 webcite]
• [3]McNeal JE, Redwine EA, Freiha FS, Stamey TA: Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988, 12:897-906.
• [4]Ismail M, Gomella LG: Ultrasound for prostate imaging and biopsy. Curr Opin Urol 2001, 11:471.
• [5]Halpern EJ: Contrast-enhanced ultrasound imaging of prostate cancer. Rev Urol 2006, 8:S29.
• [6]Salvatore V, Borghi A, Piscaglia F: Contrast-enhanced ultrasound for liver imaging: recent advances. Curr Pharm Des 2012, 18:2236-2252.
• [7]Correas J-M, Bridal L, Lesavre A, Méjean A, Claudon M, Hélénon O: Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts. Eur Radiol 2001, 11:1316-1328.
• [8]Frauscher F, Pallwein L, Klauser A, Berger A, Koppelstaetter F, Gradl J, Schurich M, Bektic J, Pinggera G, Halpern E: Ultrasound contrast agents and prostate cancer. Radiologe 2005, 45:544.
• [9]Sugimoto K, Moriyasu F, Shiraishi J, Saito K, Taira J, Saguchi T, Imai Y: Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol 2012, 22:1205-1213.
• [10]Gerst S, Hann LE, Li D, Gonen M, Tickoo S, Sohn MJ, Russo P: Evaluation of renal masses with contrast-enhanced ultrasound: initial experience. Am J Roentgenol 2011, 197:897-906.
• [11]Tang J, Yang J-C, Luo Y, Li J, Li Y, Shi H: Enhancement characteristics of benign and malignant focal peripheral nodules in the peripheral zone of the prostate gland studied using contrast-enhanced transrectal ultrasound. Clin Radiol 2008, 63:1086-1091.
• [12]Yang JC, Tang J, Li Y, Fei X, Shi H: Contrast-enhanced transrectal ultrasound for assessing vascularization of hypoechoic BPH nodules in the transition and peripheral zones: comparison with pathological examination. Ultrasound Med Biol 2008, 34:1758-1764.
• [13]Leen E, Angerson W, Yarmenitis S, Bongartz G, Blomley M, Del Maschio A, Summaria V, Maresca G, Pezzoli C, Llull J: Multi-centre clinical study evaluating the efficacy of SonoVue™(BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 2002, 41:200-206.
• [14]Ma F, Cang Y, Zhao B, Liu Y, Wang C, Liu B, Wu T, Song Y, Peng A: Contrast-enhanced ultrasound with SonoVue could accurately assess the renal microvascular perfusion in diabetic kidney damage. Nephrol Dial Transplant 2012, 27:2891-2898.
• [15]Kitano M, Kudo M, Maekawa K, Suetomi Y, Sakamoto H, Fukuta N, Nakaoka R, Kawasaki T: Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut 2004, 53:854-859.
• [16]Cosgrove D: Ultrasound contrast agents: an overview. Eur J Radiol 2006, 60:324-330.
• [17]Jiang J, Chen YQ, Zhu YK, Yao XH, Qi J: Factors influencing the degree of enhancement of prostate cancer on contrast-enhanced transrectal ultrasonography: correlation with biopsy and radical prostatectomy specimens. Br J Radiol 2012, 85:e979-e986.
• [18]Bertolotto M, Trincia E, Zappetti R, Bernich R, Savoca G, Cova MA: Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol Med 2009, 114:1106-1114.
• [19]Weingartner K, Ben-Sasson SA, Stewart R, Richie J, Riedmiller H, Folkman J: Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment. J Urol 1998, 159:465-470.
• [20]Strohmeyer D, Rössing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, Loening S: Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000, 45:216-224.
• [21]Lee CH, Akin-Olugbade O, Kirschenbaum A: Overview of prostate anatomy, histology, and pathology. Endocrinol Metab Clin N Am 2011, 40:565.
• [22]Deering RE, Bigler SA, Brown M, Brawer MK: Microvascularity in benign prostatic hyperplasia. Prostate 1995, 26:111-115.
• [23]Ren J, Huan Y, Wang H, Chang Y-J, Zhao H-T, Ge Y-L, Liu Y, Yang Y: Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin Radiol 2008, 63:153-159.
• [24]Tang J, Wang Z, Li J, Luo Y, Wang W, Xu J, Shi H: A preliminary study of contrast-enhanced ultrasound in benign prostatic hyperplasia. Zhonghua Nan Ke Xue 2007, 13:584.
• [25]Tian Y, Zhao L, Zhang H, Liu X, Zhao L, Zhao X, Li Y, Li J: AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol 2014, 9:42.
• [26]Bueno G, Fernandez-Carrobles M-M, Deniz O, Salido J, Vallez N, Garcia-Rojo M: An entropy-based automated approach to prostate biopsy ROI segmentation. Diagn Pathol 2013, 8:S24.